Compare Stryker Corporation (SYK) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs ProShares UltraPro QQQ ETF — how do they compare? Stryker Corporation trades at $277.34 (market cap $106.24B), while ProShares UltraPro QQQ ETF trades at $81.38 (market cap $38.74B). The key difference: Stryker Corporation is far larger — about 2.7× ProShares UltraPro QQQ ETF's market cap, and Stryker Corporation pays a 1.27% dividend while ProShares UltraPro QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| SYK | TQQQ | |
|---|---|---|
Market Cap | $106.24B | $38.74B |
Volume | 2,982,001 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.35 | $87.22 |
52-Week Low | $269.75 | $37.89 |
Typical Hold Time | 21 Days | 24 Days |
Enterprise Value | $117.70B | — |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
TQQQ trades at $81.16, down 2.92% on the day, with technical indicators showing a bullish overall signal despite recent selling pressure. The leveraged ETF structure amplifies both gains and losses, with recent news highlighting hidden costs beyond the stated 0.82% expense ratio. Support levels are established at $78 and $76, while resistance sits at $83 and $85.
The outlook for TQQQ remains tied to Nasdaq-100 performance and tech sector momentum, though volatility decay and financing costs present significant long-term risks. Current technical positioning suggests potential for near-term upside if support holds, but investors should be cautious of amplified losses during market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
